Latigo Biotherapeutics (NASDAQ:LTGO) Stock Moved Up to Hold by Wall Street Zen

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently commented on the company. Weiss Ratings began coverage on Latigo Biotherapeutics in a report on Tuesday. They issued a “sell (e-)” rating for the company. Guggenheim began coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price objective for the company. Leerink Partners began coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 price target for the company. The Goldman Sachs Group began coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $73.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $50.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.25.

Latigo Biotherapeutics Stock Performance

Shares of NASDAQ:LTGO opened at $12.60 on Friday. Latigo Biotherapeutics has a 1-year low of $10.24 and a 1-year high of $25.93. The business’s fifty day simple moving average is $17.95.

Latigo Biotherapeutics (NASDAQ:LTGO) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.55) EPS for the quarter.

Insider Buying and Selling at Latigo Biotherapeutics

In related news, Director James Tananbaum acquired 140,000 shares of the stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the director owned 2,008,024 shares in the company, valued at approximately $36,144,432. The trade was a 7.49% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Latigo Biotherapeutics News Roundup

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Latigo reported a third-quarter loss of $0.55 per share, beating analyst estimates by $0.12. Earnings estimate beat
• Positive Sentiment: The company says Phase 3 bunionectomy and open-label safety trials for onzotrigine remain on track to begin, with topline results expected in the second half of 2027. Third-quarter results and business highlights
• Positive Sentiment: Latigo appointed pain-sector executive Todd Smith as president and CEO. His commercialization experience could support the company’s plans to advance and potentially commercialize non-opioid pain treatments. CEO appointment
• Neutral Sentiment: LTGO trading was temporarily paused twice under limit-up/limit-down volatility rules. The pauses indicate heightened volatility, not a specific direction or cause.
• Negative Sentiment: Despite beating estimates, Latigo still reported a quarterly loss, and the expected Phase 3 readout is not until the second half of 2027, leaving substantial time and clinical-development risk before a potential catalyst. Third-quarter and nine-month results

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing non-opioid treatments for pain. The company focuses on therapies designed to selectively target Nav1.8, a sodium channel expressed in peripheral sensory neurons that plays an important role in the transmission of pain signals.

Latigo’s lead product candidate, LTG-001, is an oral, selective Nav1.8 inhibitor being developed for the treatment of acute and chronic pain conditions. By targeting pain signaling outside the central nervous system, the company aims to develop alternatives to opioid medicines and other pain treatments that may carry significant safety or tolerability concerns.